Trials / Completed
CompletedNCT02807974
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
A Study of CS-3150 to Evaluate Efficacy and Safety in Hypertensive Patients With Type 2 Diabetes and Albuminuria.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-3150 | CS-3150 1.25 to 2.5, 5mg, orally |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2016-06-21
- Last updated
- 2018-12-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02807974. Inclusion in this directory is not an endorsement.